Larvol Delta - A-52Week-Study-Evaluating-the-Efficacy-and-Safety-of-Arumakimig-MAS825-in-Participants-With-VEXAS-Followed-by-OpenLabel-Extension-OLE-Period

arumakimig (MAS825) - Novartis

http://clinicaltrials.gov/ct2/show/NCT07748624

Sep 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next